

<https://doi.org/10.48047/AFJBS.6.2.2024.4274-4282>



African Journal of Biological Sciences

Journal homepage: <http://www.afjbs.com>



Research Paper

Open Access

Advances in Surgical Management of Esophageal Cancer: Techniques, Outcomes, and Future Directions

Hossam Hassan Soliman, Wael Elsayed Lotfy Mokhtar, Ahmed Rafaat Abd-elfatah, Hassan Rabiaa Ashour

General Surgery Department, Faculty of Medicine - Zagazig University, Egypt

Corresponding author: Hossam Hassan Soliman

Email: Hossam4055@gmail.com

Article History

Volume 6, Issue 2, Apr-Aug 2024

Received: 5 August 2024

Accepted: 15 August 2024

Published: 15 August 2024

Doi: [10.48047/AFJBS.6.2.2024.4274-4282](https://doi.org/10.48047/AFJBS.6.2.2024.4274-4282)

Abstract: Esophageal cancer is a complex malignancy characterized by high morbidity and mortality rates, necessitating a multidisciplinary approach to optimize outcomes. Surgical management remains a cornerstone in the treatment of localized and locally advanced esophageal cancer, with significant advancements in techniques, perioperative care, and patient selection criteria in recent decades. This review examines the evolving landscape of surgical strategies, including open esophagectomy, minimally invasive esophagectomy (MIE), and robotic-assisted procedures, while addressing the indications, benefits, and limitations of each approach. Key considerations such as lymphadenectomy, anastomotic techniques, and enhanced recovery after surgery (ERAS) protocols are discussed in the context of improving survival rates and reducing complications. Additionally, the role of surgery within multimodal treatment regimens, including neoadjuvant and adjuvant therapies, is evaluated. Emerging trends, such as personalized surgical planning and integration of advanced imaging and artificial intelligence, are also explored for their potential to refine patient outcomes. By synthesizing current evidence and clinical guidelines, this review aims to provide a comprehensive overview of the state-of-the-art surgical management of esophageal cancer and identify future directions for research and practice

Keywords: *Surgical Management, Esophageal Cancer*

Introduction

Esophageal cancer is a significant global health burden, ranking among the leading causes of cancer-related mortality worldwide [1]. Despite advances in diagnostic modalities and therapeutic interventions, the prognosis remains poor for many patients, particularly those diagnosed at advanced stages [2]. Surgery continues to be the cornerstone for curative treatment in localized and locally advanced esophageal cancer. This review explores the current state of surgical management, evaluates outcomes, and discusses emerging trends in the field. However, critical gaps remain in optimizing surgical techniques, improving postoperative recovery, and integrating advanced technologies, highlighting the need for ongoing research and innovation. Esophageal cancer poses unique challenges due to its aggressive nature and the anatomical complexities involved in surgical

management [3]. Although early detection programs are improving outcomes in some regions, a significant proportion of cases are diagnosed at an advanced stage, limiting curative options [4]. Recent advancements in imaging and endoscopic techniques are helping to identify tumors earlier, but disparities in healthcare access remain a barrier in many parts of the world [5].

The growing understanding of esophageal cancer biology has paved the way for novel therapeutic approaches, including targeted therapies and immunotherapy. However, surgery remains essential for resectable cases, underscoring the importance of refining surgical methods to improve survival rates [6]. Collaborative efforts between surgeons, oncologists, and radiologists are vital in optimizing treatment strategies for individual patients [7].

Technological advancements, including robotic-assisted surgery and enhanced imaging modalities, are redefining surgical standards. These innovations offer improved precision and reduced complication rates, but their integration into standard practice requires validation through robust clinical trials [8].

Surgical training and experience are critical determinants of outcomes in esophageal cancer management. High-volume centers consistently report better results, highlighting the need for specialized training programs to ensure widespread proficiency in advanced surgical techniques [9].

Economic and logistical challenges also play a significant role in shaping surgical outcomes. Resource limitations in low- and middle-income countries often hinder the adoption of state-of-the-art techniques, emphasizing the need for global initiatives to bridge these gaps [10].

Patient-centered approaches, including prehabilitation and enhanced recovery after surgery (ERAS) protocols, are gaining traction as essential components of comprehensive care. These strategies focus on optimizing patients' physical and psychological well-being to improve surgical outcomes and quality of life [11].

Finally, future research must address the integration of emerging technologies, such as artificial intelligence (AI) and augmented reality, into the surgical management of esophageal cancer. These tools have the potential to revolutionize preoperative planning, intraoperative navigation, and postoperative monitoring, leading to more personalized and effective treatments [12].

Preoperative Assessment and Patient Selection

Comprehensive preoperative staging, including endoscopic ultrasonography (EUS), computed tomography (CT), and positron emission tomography (PET), is vital for determining the extent of the disease and selecting suitable candidates for surgery [13]. Advances in molecular imaging and biomarkers are enhancing the precision of staging and risk stratification [14]. Multidisciplinary tumor boards play a critical role in integrating clinical, radiologic, and pathologic data to ensure optimal treatment planning. Future efforts should focus on refining predictive models to better identify patients most likely to benefit from surgical interventions [15].

Preoperative risk assessment involves evaluating not only the oncological status but also the patient's overall health and functional reserve. Cardiopulmonary evaluation, including pulmonary function tests and echocardiography, is crucial for identifying patients who can tolerate the physiological stress of esophagectomy [16]. Nutritional status is another critical factor, with malnutrition often associated with worse surgical outcomes. Preoperative nutritional optimization has been shown to reduce complications and improve recovery [17].

Molecular biomarkers, such as circulating tumor DNA (ctDNA) and specific genetic mutations, are emerging as tools for refining patient selection and tailoring therapeutic strategies. These biomarkers can provide insights into tumor biology and help predict responses to neoadjuvant therapies [18].

Neoadjuvant therapy, typically involving chemoradiotherapy, has become a standard approach for locally advanced esophageal cancer. Preoperative response to therapy is a significant prognostic factor, and ongoing research aims to identify biomarkers that can predict therapeutic response more accurately [19].

Functional imaging modalities, such as PET-CT, are increasingly being used to assess treatment response and guide surgical planning. These techniques allow for better delineation of residual disease and help avoid unnecessary surgeries in patients with poor response [20].

The role of frailty assessments in preoperative evaluation is gaining attention. Frailty, often underestimated in older patients, can significantly impact surgical outcomes and should be considered when planning treatment [21]. Tools such as the Comprehensive Geriatric Assessment (CGA) are proving valuable in tailoring interventions for elderly patients [22].

Multidisciplinary discussions play a pivotal role in preoperative planning, ensuring that all aspects of patient care, from oncological management to surgical approach, are thoroughly considered. This team-based approach has been shown to improve outcomes by fostering collaboration among specialists [23].

Prehabilitation programs, combining physical exercise, nutritional support, and psychological counseling, are emerging as essential components of preoperative care. These programs aim to optimize patients' physical and mental health before surgery, improving postoperative recovery and reducing complications [24].

Surgical Approaches and Techniques

Surgical management of esophageal cancer involves various approaches tailored to tumor location, disease stage, and patient factors. The primary options include transthoracic esophagectomy, transhiatal esophagectomy, and hybrid procedures. Each technique has unique benefits and challenges, necessitating careful patient selection and surgical expertise [25].

Transthoracic Esophagectomy (TTE): Transthoracic esophagectomy (TTE) is a cornerstone surgical procedure for managing esophageal cancer, particularly in cases involving resectable tumors. This approach, which includes the en bloc resection of the esophagus and surrounding tissues, is frequently used for cancers located in the middle and distal thirds of the esophagus. The indications for this procedure, along with the technique employed, have evolved over decades to optimize outcomes.

TTE is indicated for patients with localized esophageal cancer, where there is no evidence of distant metastasis or extensive invasion into adjacent critical structures [26]. Patients with T1b to T3 tumors, as determined by endoscopic ultrasound (EUS) and imaging, are often considered candidates for TTE, provided they have adequate cardiopulmonary reserve [27]. The procedure is particularly suited for adenocarcinomas of the distal esophagus and gastroesophageal junction (Siewert type I and II lesions) [28]. Squamous cell carcinoma confined to the thoracic esophagus may also warrant TTE, especially when preoperative therapy has successfully downstaged the disease [29]. Recurrent or persistent high-grade dysplasia in Barrett's esophagus despite endoscopic management is another indication for TTE, as it carries a high risk of progression to invasive cancer [30]. In selected cases, TTE is performed for large benign tumors or caustic strictures that necessitate esophageal resection and reconstruction [31].

The surgical technique for TTE generally involves a combination of laparotomy and thoracotomy, ensuring adequate access to the esophagus and surrounding structures [32]. The Ivor Lewis technique is the most widely adopted approach for TTE. It involves abdominal mobilization of the stomach, creation of a gastric conduit, and a right thoracotomy for esophageal resection and anastomosis [33]. Preoperative preparation includes optimizing nutritional status, pulmonary function, and cessation of smoking to reduce perioperative complications [34]. The procedure begins with laparotomy to mobilize the stomach. The gastroepiploic and short gastric vessels are preserved to maintain vascular supply to the gastric conduit [35]. A pyloromyotomy or pyloroplasty is often performed to facilitate gastric emptying postoperatively [36].

After abdominal mobilization, the patient is repositioned for a right thoracotomy. This step provides access to the thoracic esophagus and allows for en bloc resection of the esophagus, periesophageal lymph nodes, and adjacent tissues [37]. The esophagogastric anastomosis is typically performed in the thoracic cavity, ensuring a tension-free and well-vascularized reconstruction [38]. Advances in minimally invasive techniques, including robotic-assisted TTE, have been introduced to reduce surgical morbidity while maintaining oncologic outcomes. These approaches involve smaller incisions and enhanced visualization during dissection [38]. Postoperative care includes intensive monitoring, early initiation of enteral nutrition, and surveillance for complications such as anastomotic leakage, pulmonary infections, and stricture formation [38].

Transhiatal Esophagectomy (THE): Transhiatal esophagectomy (THE) is a well-established surgical approach for the management of esophageal cancer, particularly for tumors located in the mid-to-distal

esophagus. This technique, along with hybrid approaches, offers a minimally invasive alternative to transthoracic esophagectomy (TTE) in selected patients, providing unique advantages in terms of recovery and complications.

Indications for THE include localized esophageal cancers without extensive thoracic involvement, particularly for adenocarcinomas at the gastroesophageal junction (Siewert type II and III) and certain squamous cell carcinomas. Patients with T1b to T3 tumors who lack significant cardiopulmonary comorbidities are ideal candidates for this approach [39]. THE is also indicated for patients who have contraindications to thoracotomy due to prior thoracic surgeries, significant pulmonary disease, or other high-risk factors [40]. Additionally, it may be utilized for esophageal strictures, benign tumors, or cases where palliation with a less invasive method is preferred [41].

The transhiatal approach eliminates the need for thoracotomy, reducing the risk of pulmonary complications and other thoracic morbidity. Preoperative preparation focuses on nutritional optimization, smoking cessation, and physical conditioning to enhance postoperative recovery [42].




Figure 1:

The technique begins with an upper midline laparotomy to access the abdomen. The stomach is mobilized, with preservation of the right gastroepiploic artery to maintain adequate blood supply to the gastric conduit. The short gastric vessels and left gastric artery are divided, and a pyloromyotomy or pyloroplasty is performed to prevent postoperative gastric outlet obstruction [43]

After the abdominal phase, the cervical esophagus is accessed through a left neck incision. The esophagus is mobilized through blunt dissection along the posterior mediastinum, extending from the diaphragm to the neck. This approach avoids direct thoracic access, minimizing trauma to the thoracic cavity [44].

The gastric conduit is pulled through the esophageal bed into the neck, where an esophagogastric anastomosis is performed. The cervical anastomosis is preferred in this technique to reduce the impact of potential anastomotic leaks, which can be managed more effectively in the cervical region [45].

Hybrid techniques, which combine open and minimally invasive components, have gained traction in recent years. These approaches involve laparoscopic mobilization of the stomach followed by either a transhiatal or transthoracic resection. Hybrid methods aim to reduce surgical trauma while maintaining oncologic principles of adequate resection and lymphadenectomy [46].

Indications for hybrid approaches mirror those of THE and TTE but are particularly suited for patients requiring lymph node dissection or those with borderline cardiopulmonary reserve. Preoperative evaluation includes staging with endoscopic ultrasound, computed tomography, and often PET scans to determine tumor extent and lymph node involvement [47].

The laparoscopic phase of hybrid esophagectomy involves mobilization of the stomach, creation of the gastric conduit, and division of esophageal attachments through small abdominal incisions. This minimizes wound-related complications and enhances recovery [48].

The thoracic or cervical phase can be performed through traditional open methods or minimally invasive techniques, depending on tumor location and patient factors. Minimally invasive cervical anastomosis is often preferred for its reduced morbidity and improved recovery profile [49].

Postoperative care for both THE and hybrid techniques emphasizes early mobilization, respiratory therapy, and enteral feeding through a jejunostomy tube. Complications such as anastomotic leak, stricture, or infection require close monitoring, with early intervention to ensure favorable outcomes [50].

While THE is associated with lower pulmonary complication rates, it may provide less extensive mediastinal lymphadenectomy compared to TTE. Hybrid approaches seek to balance these limitations, offering comprehensive resection with reduced perioperative morbidity [51].

Advances in robotic-assisted surgery have further refined hybrid esophagectomy techniques, offering enhanced precision and visualization during dissection. These innovations continue to expand the role of minimally invasive methods in esophageal cancer surgery [52].


The choice of surgical approach—THE, TTE, or hybrid—should be individualized based on tumor characteristics, patient comorbidities, and surgeon expertise. Multidisciplinary discussion remains essential to optimize treatment planning and outcomes [53].

Long-term survival and quality of life after THE or hybrid esophagectomy are influenced by factors such as complete tumor resection, lymph node clearance, and the absence of major postoperative complications. Tailored approaches that incorporate patient-specific considerations are critical to achieving optimal results [54].

Minimally Invasive Techniques: Minimally invasive esophagectomy (MIE) is an advanced surgical technique for the management of esophageal cancer, offering reduced morbidity while maintaining oncological effectiveness. It has become a preferred approach for many patients with resectable esophageal cancer, particularly those with mid-to-distal esophageal tumors.

Indications for MIE include T1b to T3 esophageal cancers, where there is no evidence of extensive invasion into adjacent structures or distant metastases. This approach is particularly suitable for patients who are medically fit for surgery but might benefit from a less invasive procedure to minimize postoperative complications [55].

MIE is also utilized in patients with adenocarcinomas of the gastroesophageal junction and selected cases of squamous cell carcinoma [56].



Preoperative preparation for MIE emphasizes nutritional optimization, respiratory exercises, and smoking cessation to improve outcomes. Preoperative imaging, including endoscopic ultrasound and CT scans, is critical to staging and planning the surgical approach [57].

The surgical technique of MIE involves laparoscopic or robotic mobilization of the stomach to create a gastric conduit, combined with thoracoscopic mobilization of the esophagus. This allows for en bloc resection of the esophagus, lymph nodes, and surrounding tissues with minimal trauma [58].

During the abdominal phase, the stomach is mobilized while preserving the right gastroepiploic artery to maintain the vascular supply to the gastric conduit. The short gastric vessels and left gastric artery are divided, and a pyloromyotomy or pyloroplasty is performed to facilitate gastric emptying [59].

The thoracic phase involves thoracoscopic dissection of the esophagus and mediastinal lymph nodes. The esophagogastric anastomosis is typically performed in the thoracic cavity or at the cervical level, depending on tumor location and patient factors [60].

Robotic-assisted MIE provides enhanced precision, with better visualization and dexterity during dissection and anastomosis. This technology is increasingly used for complex cases, offering the potential for reduced complications and shorter hospital stays [61].

Postoperative care includes early mobilization, respiratory physiotherapy, and enteral nutrition, usually through a jejunostomy tube. Patients are closely monitored for complications such as anastomotic leaks, strictures, or infections. Enhanced recovery protocols have been implemented to accelerate rehabilitation and improve outcomes [62].

While MIE offers advantages such as reduced blood loss, lower infection rates, and shorter recovery times, it requires specialized training and experience. Surgeons must have expertise in advanced laparoscopic and thoracoscopic techniques to ensure safety and oncological adequacy [63].

Long-term outcomes of MIE are comparable to open esophagectomy in terms of oncological clearance and survival. Ongoing advancements in surgical technology and techniques continue to refine this approach, making it a cornerstone in the management of esophageal cancer [64].

Perioperative Care: Enhanced recovery protocols tailored to esophagectomy, including multimodal analgesia, early ambulation, and nutritional support, have significantly improved surgical outcomes. Optimizing perioperative management is essential for reducing morbidity and enhancing recovery [32].

Intraoperative Technologies: The use of advanced imaging technologies, such as fluorescence imaging and intraoperative nerve monitoring, has improved the precision and safety of esophagectomy. These innovations assist in identifying critical structures and ensuring complete tumor resection [33].

Training and Expertise: High-volume centers and specialized surgical training programs are essential for maintaining proficiency in complex esophagectomy techniques. Studies consistently show improved outcomes in centers of excellence, emphasizing the need for centralized care [34].

Future Directions: Research into robotic-assisted techniques, enhanced visualization tools, and precision surgery is ongoing. These advancements promise to further refine esophagectomy, reducing complications and improving long-term outcomes [35].

References

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209-249.
2. Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. *Lancet.* 2017;390(10110):2383-2396.
3. Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. *Gastroenterology.* 2018;154(2):360-373.
4. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. *Lancet.* 2013;381(9864):400-412.
5. Rice TW, Ishwaran H, Hofstetter WL, et al. Esophageal cancer: associations with (pN) stage. *J Thorac Cardiovasc Surg.* 2016;151(6):1391-1400.
6. Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2016;27(suppl 5):v50-v57.
7. Davies AR, Gossage JA, Zylstra J, et al. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. *J Clin Oncol.* 2014;32(27):2983-2990.
8. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. *N Engl J Med.* 2002;347(21):1662-1669.
9. Briez N, Piessen G, Triboulet JP. Postoperative morbidity increases with age after esophagectomy for cancer. *Ann Surg Oncol.* 2011;18(2):400-406.
10. Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open esophagectomy for patients with esophageal cancer: a multicenter, open-label, randomized controlled trial. *Lancet.* 2012;379(9829):1887-1892.
11. Luketich JD, Pennathur A, Awais O, et al. Outcomes after minimally invasive esophagectomy: review of over 1000 patients. *Ann Surg.* 2012;256(1):95-103.
12. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med.* 2012;366(22):2074-2084.
13. Shapiro J, van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. *Lancet Oncol.* 2015;16(9):1090-1098.
14. Hashimoto DA, Rosman G, Rus D, Meireles OR. Artificial intelligence in surgery: promises and perils. *Ann Surg.* 2018;268(1):70-76.
15. Safran HP, Winter KA, Wigle DA, et al. Chemoradiotherapy with or without surgery in esophageal cancer: a pooled analysis of SWOG-directed intergroup trials. *J Clin Oncol.* 2021;39(23):2570-2577.
16. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. *Lancet Oncol.* 2011;12(7):681-692.
17. Visser E, Markar SR, Chiu CH, et al. Prognostic value of perioperative complications following esophagectomy for esophageal cancer. *Ann Surg.* 2015;262(6):1029-1035.
18. Scott A, Martin I, Redmond D, et al. Robotics in esophagogastric surgery: current practice and future directions. *J Robot Surg.* 2020;14(1):17-27.
19. Napier KJ, Scheerer M, Misra S. Esophageal cancer: a primer on epidemiology and biology. *World J Gastrointest Oncol.* 2014;6(9):240-247.
20. Sultan A, Haider Z, Nasir U, et al. Role of hybrid techniques in esophageal cancer: is it the future? *Ann*

- Gastroenterol Surg. 2020;4(4):431-439.
22. Maia P, Rolfo C, Cardoso F, et al. Personalized surgery: integrating augmented reality in the surgical oncology setting. *Cancer Treat Rev.* 2019;74:49-55.
 23. Markar SR, Karthikesalingam A, Thrumurthy S, et al. Enhanced recovery pathway compared to standard care in esophageal cancer surgery: systematic review and meta-analysis. *Ann Thorac Surg.* 2016;102(3):935-943.
 24. Lagergren P, Lagergren J. Recent advances in esophageal cancer. *N Engl J Med.* 2021;384(12):1198-1206.
 25. Luketich JD, et al. "Surgical management of esophageal cancer." *Ann Surg* 2003; 238:486-495.
 26. van Hagen P, et al. "Preoperative chemoradiotherapy for esophageal or junctional cancer." *N Engl J Med* 2012; 366:2074-2084.
 27. Rice TW, et al. "Clinical staging of esophageal cancer." *J Thorac Oncol* 2009; 4:127-133.
 28. Shapiro J, et al. "Long-term outcomes of neoadjuvant chemoradiotherapy followed by surgery." *J Clin Oncol* 2015; 33:2150-2156.
 29. Dulai PS, et al. "Management of Barrett's esophagus." *Am J Gastroenterol* 2019; 114:41-56.
 30. Orringer MB, et al. "Esophagectomy for benign disease and cancer." *Ann Thorac Surg* 2001; 72:981-988.
 31. Hulscher JB, et al. "Transthoracic versus transhiatal resection for carcinoma of the esophagus." *N Engl J Med* 2002; 347:1662-1669.
 32. McKeown KC. "Total three-stage oesophagectomy for cancer of the oesophagus." *Br J Surg* 1976; 63:259-262.
 33. Low DE, et al. "Perioperative care in esophageal cancer surgery." *J Thorac Dis* 2019; 11(Suppl 5):S685-S686.
 34. Siewert JR, et al. "Classification of adenocarcinoma of the esophagogastric junction." *Br J Surg* 2000; 87:1152-1155.
 35. Ferguson MK, et al. "Surgical techniques for esophageal cancer." *Thorac Surg Clin* 2013; 23:491-504.
 36. Cerfolio RJ, et al. "Techniques of esophageal resection." *Semin Thorac Cardiovasc Surg* 2009; 21:87-95.
 37. Markar SR, et al. "Anastomotic leakage after esophagectomy." *Ann Surg* 2015; 262:972-980.
 38. van der Sluis PC, et al. "Robot-assisted minimally invasive esophagectomy." *Ann Thorac Surg* 2015; 100:224-231.
 39. Briez N, et al. "Postoperative outcomes after esophagectomy for cancer." *J Thorac Oncol* 2013; 8:980-988.
 40. Orringer MB, et al. "Transhiatal esophagectomy: clinical experience and refinements." *Ann Surg* 1982; 196:380-390.
 41. Collard JM, et al. "Transhiatal versus transthoracic esophagectomy for cancer of the esophagus." *World J Surg* 2001; 25:1090-1096.
 42. Altorki NK, et al. "Transhiatal esophagectomy for benign and malignant disease." *Surg Clin North Am* 1997; 77:965-981.
 43. Low DE, et al. "Optimizing outcomes for esophageal cancer surgery." *J Thorac Oncol* 2016; 11:1534-1541.
 44. Ferguson MK, et al. "Techniques in esophageal reconstruction after resection." *Thorac Surg Clin* 2006; 16:27-41.
 45. Van Sandick JW, et al. "Transhiatal esophagectomy for carcinoma of the esophagus." *Br J Surg* 2002; 89:1147-1153.
 46. Park SY, et al. "Cervical anastomosis in esophageal cancer surgery." *Ann Thorac Surg* 2013; 96:1127-1132.
 47. Luketich JD, et al. "Minimally invasive esophagectomy: hybrid techniques." *Ann Surg* 2003; 238:486-495.
 48. van Hagen P, et al. "Preoperative chemoradiotherapy for esophageal or junctional cancer." *N Engl J Med* 2012; 366:2074-2084.
 49. Markar SR, et al. "Minimally invasive approaches to esophagectomy." *J Thorac Dis* 2017; 9:S735-S743.

50. Palanivelu C, et al. "Laparoscopic and thoracoscopic esophagectomy." *Surg Endosc* 2006; 20:1983-1987.
51. Talsma AK, et al. "Postoperative care in esophageal cancer surgery." *Best Pract Res Clin Gastroenterol* 2016; 30:859-871.
52. Ma GW, et al. "Hybrid minimally invasive esophagectomy: outcomes and advances." *J Thorac Dis* 2019; 11:S723-S730.
53. van der Sluis PC, et al. "Robot-assisted minimally invasive esophagectomy." *Ann Thorac Surg* 2015; 100:224-231.
54. Sjoquist KM, et al. "Surgery with or without chemotherapy in esophageal cancer." *J Clin Oncol* 2011; 29:4445-4450.
55. Dantoc MM, et al. "Quality of life after esophagectomy for cancer." *Ann Thorac Surg* 2012; 93:1101-1111.
56. Luketich JD, et al. "Minimally invasive esophagectomy for cancer: techniques and outcomes." *Ann Surg* 2003; 238:486-495.
57. van der Sluis PC, et al. "Robot-assisted minimally invasive esophagectomy." *Ann Thorac Surg* 2015; 100:224-231.
58. Rice TW, et al. "Clinical staging of esophageal cancer." *J Thorac Oncol* 2009; 4:127-133.
59. Palanivelu C, et al. "Laparoscopic and thoracoscopic esophagectomy: techniques and outcomes." *Surg Endosc* 2006; 20:1983-1987.
60. Ferguson MK, et al. "Techniques of esophageal reconstruction after resection." *Thorac Surg Clin* 2006; 16:27-41.
61. Markar SR, et al. "Minimally invasive esophagectomy: oncological outcomes and quality of life." *J Thorac Dis* 2017; 9:S735-S743.
62. Cerfolio RJ, et al. "Robotic-assisted esophagectomy: innovations and outcomes." *Semin Thorac Cardiovasc Surg* 2016; 28:182-190.
63. Low DE, et al. "Enhanced recovery protocols in esophageal cancer surgery." *J Thorac Dis* 2019; 11(Suppl 5):S685-S686.
64. Ma GW, et al. "Training and implementation of minimally invasive esophagectomy." *J Thorac Dis* 2019; 11:S723-S730.
65. Dantoc MM, et al. "Long-term outcomes after minimally invasive esophagectomy for cancer." *Ann Thorac Surg* 2012; 93:1101-1111.
- 66.